Novo Nordisk (NVO) stock in focus as company announces new Phase 3 trial for its next-gen weight loss drug CagriSema despite ...
CagriSema, which underperformed expectations in its first Phase 3 test, will be studied at different doses and for longer ...
15hon MSN
Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.
The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback